Tumor Control and Normal Tissue Complication Probability Modeling for High Dose Rate Brachytherapy Followed by 5-Fraction SBRT Treatment of Unfavorable Intermediate or High-risk Prostate Cancer Patients with Biodegradable Hydrogel Rectal Spacer Placement
International Journal of Radiation Oncology*Biology*Physics · 2026-09 · 126 (1) · e585
DOI: 10.1016/j.ijrobp.2026.06.1933 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-09. Verfasst von K.C. Huang und 4 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Huang, K., Ng, S., Ishaq, O., Prabhu, A., & Pokhrel, D. (2026). Tumor Control and Normal Tissue Complication Probability Modeling for High Dose Rate Brachytherapy Followed by 5-Fraction SBRT Treatment of Unfavorable Intermediate or High-risk Prostate Cancer Patients with Biodegradable Hydrogel Rectal Spacer Placement. International Journal of Radiation Oncology*Biology*Physics, 126(1), e585. https://doi.org/10.1016/j.ijrobp.2026.06.1933
Vancouver
Huang K, Ng S, Ishaq O, Prabhu A, Pokhrel D. Tumor Control and Normal Tissue Complication Probability Modeling for High Dose Rate Brachytherapy Followed by 5-Fraction SBRT Treatment of Unfavorable Intermediate or High-risk Prostate Cancer Patients with Biodegradable Hydrogel Rectal Spacer Placement. International Journal of Radiation Oncology*Biology*Physics. 2026;126(1):e585. doi:10.1016/j.ijrobp.2026.06.1933
BibTeX
@article{Huang2026,
author = {Huang, K.C. and Ng, S.K. and Ishaq, O. and Prabhu, A.V. and Pokhrel, D.},
title = {Tumor Control and Normal Tissue Complication Probability Modeling for High Dose Rate Brachytherapy Followed by 5-Fraction SBRT Treatment of Unfavorable Intermediate or High-risk Prostate Cancer Patients with Biodegradable Hydrogel Rectal Spacer Placement},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
volume = {126},
number = {1},
pages = {e585},
doi = {10.1016/j.ijrobp.2026.06.1933}
}
EUVIMED